Eiger BioPharmaceuticals appoints Christine Murray to its Board of Directors

– USA, CA –  Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare and ultra-rare diseases, announced today the appointment of Christine Murray, MS, RAC to its Board of Directors.

Ms. Murray is a pharmaceutical industry veteran with broad regulatory experience spanning over two decades in large pharma and biotechnology companies across diverse therapeutic areas including liver disease, metabolic disease, antivirals, and rare and ultra-rare disease programs, with multiple successful international regulatory submissions and outcomes.  Ms. Murray is currently Senior Vice President of Global Regulatory Affairs at Ultragenyx Pharmaceutical, Inc.

“Ms. Murray has an extensive track record in leading teams through complex regulatory processes, interacting with regulatory agencies including FDA and EMA, and successfully negotiating regulatory approval pathways,” said Thomas Dietz, PhD, Chairman of the Board of Eiger. “Her operational background will be invaluable as we advance the Eiger pipeline and multiple regulatory filings.  We look forward to Ms. Murray’s strategic insights and contributions to the Board and Company.”

About Christine Murray

Christine Murray is currently Senior Vice President of Global Regulatory Affairs at Ultragenyx Pharmaceutical, Inc., developing treatments for rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases.  Prior to joining Ultragenyx, Ms. Murray was Vice President of Regulatory Affairs at Raptor Pharmaceuticals, a company that developed products for serious, ultra-rare diseases.  Raptor was acquired by Horizon Pharma plc for approximately $800 million in 2017.  Prior to that, she held positions of increasing responsibility at a number of biopharma companies, including Achaogen, Inc., Alexza Pharmaceuticals, Inc., and Gilead Sciences, Inc., in Regulatory Affairs and Quality Assurance.  Ms. Murray holds a BS in Biochemistry from Liverpool University, UK, an MS in Clinical Biochemistry from the University of Newcastle-upon-Tyne, UK, and a Certification in Regulatory Affairs from the University of California Santa Cruz Extension.

“I am very pleased to join Eiger’s Board at this exciting point in the Company’s evolution and look forward to working closely with the other Board members in supporting Eiger’s management team to advance multiple, first-in-class, rare and ultra-rare disease programs to patients with unmet medical needs,” said Ms. Murray.

About Eiger

Eiger is a late-stage biopharmaceutical company focused on the accelerated development and commercialization of a pipeline of targeted, first-in-class therapies for rare and ultra-rare diseases.  The company’s lead program is in Phase 3, developing lonafarnib, a first-in-class prenylation inhibitor for the treatment of Hepatitis Delta Virus (HDV) infection.  The company is also preparing an NDA with plans to file in 2019 for lonafarnib in the treatment of Hutchinson-Gilford Progeria Syndrome (HGPS or Progeria) and Progeroid Laminopathies.
For additional information about Eiger, please visit www.eigerbio.com.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.